The pan-TRK assay provides a blood sample that can help physicians screen for NTRK fusions, biomarkers that can be used to qualify patients for TRK inhibitor therapies.
Fusions of NTRK genes encode for TRK protein receptors, and the presence of TRK proteins has been associated with more aggressive cancer in certain tumor types, such as lung cancer.
"Biocept's Target Selector pan-TRK assay utilizes our proprietary circulating tumor cell (CTC) platform, which enables a simple blood-based test to screen for TRK gene alternations, a unique liquid biopsy offering," Senior Vice President and Senior Medical Director Veena Singh said in a statement. "Biocept's novel liquid biopsy tests are designed to help physicians rapidly and in real-time identify key biomarkers of interest to facilitate the clinical decision making process."
Biocept’s pan-TRK is the company’s latest liquid biopsy test added to its library, all of which are certified by the Clinical Laboratory Improvement Amendments, a set of US regulatory standards.
"We continue to execute on expanding our menu of non-invasive and cost-effective biomarker tests," CEO Michael Nall said. "Biocept now offers 20 commercially available liquid biopsy assays including two tumor-specific next generation sequencing panels that cover the most actionable genomic alterations for solid tumors. We believe that this comprehensive offering, including the addition of our Target Selector pan-TRK test, will help us increase adoption of our liquid biopsy platform in the oncology market."
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel